Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

Sweden's Anocca is a TCR-T company with a unique approach that is going after unique targets, its first CTA will be filed soon

Plymouth Meeting based Geneos Therapeutics is developing DNA-based personalized therapeutic cancer vaccines

Houston/Philadelphia based ImmunoGenesis is trying to turn cold tumors hot with a PD‑L1/PD‑L2 dual‑specific inhibitor

Pittsburgh based Neuro-Innovators is developing three drugs to improve neuroplasticity to enhance the effectiveness of rehab post-stroke

With expertise in delivering drugs to the liver, Medivir recently had data at ESMO for its lead liver cancer drug, fostrox

Vicore Pharma's CEO describes the rationale for using angiotensin II type 2 receptor agonists in IPF

Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics

BioInvent's CEO highlights TNFR2 data recently presented at ESMO, and more in the company's pipeline

The co-founder of Stockholm's Stratipath talks digital pathology and what it was like to spin out of the prestigious Karolinska Institute

Oxford BioTherapeutics' OGAP platform, a cancer specific membrane protein library, has enabled the company to find cancer targets for its own pipeline and partners alike

Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond

Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating

Since 1986, Madrid's PharmaMar has been searching the world's oceans for new cancer medicines - it has already led to three approved drugs

Getting a general overview of protein splicing at Barcelona's SpliceBio

From Biocom California's Women's Health Conference: The Co-Founder and CEO of AccendoWave describes the importance of understanding women's pain data

Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated

In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor

Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress

The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens